


Tesamorelin 10mg
🔬 What Is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH).
It stimulates the pituitary gland to release growth hormone (GH), which in turn increases IGF-1 production.
Brand name: Egrifta SV.
It’s FDA-approved, but only for one specific medical use.
📌 Approved Use
Indication: Treatment of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
It is not approved for general weight loss, bodybuilding, or anti-aging—though some clinics prescribe it off-label.
⚙️ Mechanism of Action
Mimics natural GHRH → stimulates pulsatile GH release.
Leads to:
Increased lipolysis (fat breakdown)
Decreased lipogenesis (fat storage)
Selective reduction in visceral adipose tissue (VAT) (the deep belly fat around organs, strongly linked to metabolic disease)
May also improve liver fat and insulin sensitivity in some patients.
📊 Clinical Effects
Visceral fat reduction: Average 15–20% decrease in VAT after 6 months of therapy.
Liver health: Studies suggest benefit in NAFLD/NASH (fatty liver disease).
Lean body mass: Modest increases, but not a dramatic muscle builder.
Metabolic impact: May improve triglycerides and cholesterol, though can raise blood sugar in some patients.
⚠️ Safety & Side Effects
Common:
Injection site reactions (redness, itching)
Joint stiffness, muscle aches
Peripheral edema (swelling)
Mild nausea
Metabolic:
May raise fasting blood sugar or HbA1c → caution in people with diabetes or prediabetes.
Serious:
Avoid in patients with active cancer (since GH/IGF-1 can promote cell growth).
Contraindicated in pregnancy.
✅ Key Takeaways
Tesamorelin = FDA-approved GHRH analog, marketed as Egrifta SV.
Indication: Only approved for HIV-associated lipodystrophy (visceral fat reduction).
Dose: 2 mg SC daily.
Benefits: Decreases visceral fat, modest lean mass gains, possible liver benefits.
Risks: Injection site irritation, joint aches, possible blood sugar elevation.
🔬 What Is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH).
It stimulates the pituitary gland to release growth hormone (GH), which in turn increases IGF-1 production.
Brand name: Egrifta SV.
It’s FDA-approved, but only for one specific medical use.
📌 Approved Use
Indication: Treatment of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
It is not approved for general weight loss, bodybuilding, or anti-aging—though some clinics prescribe it off-label.
⚙️ Mechanism of Action
Mimics natural GHRH → stimulates pulsatile GH release.
Leads to:
Increased lipolysis (fat breakdown)
Decreased lipogenesis (fat storage)
Selective reduction in visceral adipose tissue (VAT) (the deep belly fat around organs, strongly linked to metabolic disease)
May also improve liver fat and insulin sensitivity in some patients.
📊 Clinical Effects
Visceral fat reduction: Average 15–20% decrease in VAT after 6 months of therapy.
Liver health: Studies suggest benefit in NAFLD/NASH (fatty liver disease).
Lean body mass: Modest increases, but not a dramatic muscle builder.
Metabolic impact: May improve triglycerides and cholesterol, though can raise blood sugar in some patients.
⚠️ Safety & Side Effects
Common:
Injection site reactions (redness, itching)
Joint stiffness, muscle aches
Peripheral edema (swelling)
Mild nausea
Metabolic:
May raise fasting blood sugar or HbA1c → caution in people with diabetes or prediabetes.
Serious:
Avoid in patients with active cancer (since GH/IGF-1 can promote cell growth).
Contraindicated in pregnancy.
✅ Key Takeaways
Tesamorelin = FDA-approved GHRH analog, marketed as Egrifta SV.
Indication: Only approved for HIV-associated lipodystrophy (visceral fat reduction).
Dose: 2 mg SC daily.
Benefits: Decreases visceral fat, modest lean mass gains, possible liver benefits.
Risks: Injection site irritation, joint aches, possible blood sugar elevation.